Phillip D. Zamore

The Zamore lab at the RTI focuses on understanding the underlying processes of RNAi; how small RNAs (miRNA, siRNA, piRNA) are involved in gene regulation networks.[3] In addition to a focus on basic research, the Zamore lab is working to develop novel nucleic acid-based drugs to treat human disease (HD).[2] Dr. Zamore has more than 40,000 citations on Google Scholar.[4]

Zamore received his A.B. in biochemistry and molecular biology from Harvard University in Cambridge, Massachusetts, in 1986 and continued graduate studies with Michael Green at Harvard, receiving his Ph.D. in 1992.[1] After completing postdoctoral studies at The Whitehead Institute for Biomedical Research at MIT and the Skirball Institute at New York University Medical Center with Ruth Lehmann, David Bartel, and James R. Williamson, Zamore began his academic career as an assistant professor in the Department of Biochemistry and Molecular Pharmacology in 1999 at UMass Medical School in Worcester, Massachusetts, where he is now the Gretchen Stone Cook Professor of Biomedical Sciences and Professor of Biochemistry and Molecular Pharmacology.

Zamore's research has led to a career in biotechnology, co-founding Alnylam Pharmaceuticals in 2002.[5] Alnylam is dedicated to bringing RNAi based therapies to market and developed the first-ever FDA approved RNAi drug, Patisiran, gaining FDA approval in August 2018.[6] In 2014, Dr. Zamore co-founded another RNAi based company; Voyager Therapeutics,[7] which focuses on developing therapeutics for neurodegenerative disorders.

• Invented Here! Honoree, Boston Patent Law Association, for US patent US 9,226,976, “RAAV- Based Compositions and Methods for Treating Alpha-1 Anti-Trypsin Deficiencies,” October 2017
• Paper of the Year (Salomon et al., Cell 2015), Oligonucleotide Therapeutics Society[8]
• Recipient, Chancellor's Medal for Excellence in Scholarship, University of Massachusetts Medical School[9]
• “The World’s Most Influential Scientific Minds 2014,” Molecular Biology & Genetics, Thomson-Reuters[10]
• Top 20 Translational Researchers of 2014, Nature Biotechnology[11]
• Fellow, National Academy of Inventors, December 2014[12]
• Outstanding Research Achievement, Nature Biotechnology SciCafé June 2009
• Schering-Plough Award, American Society of Biochemistry and Molecular Biology, April 2009
• Most Highly Cited Researchers, 2002–2012 (Thomson-Reuters)[1]
• W.M. Keck Foundation Young Scholar in Medical Research, July 2002–July 2007
• Top 20 Most Highly Cited Researchers in Molecular Biology and Genetics, 2002–2006, ScienceWatch (Thomson Scientific)[2]
• Pew Scholar in the Biomedical Sciences, July 2000–June 2004[13]

• Hutvagner, G.; McLachlan, J.; Pasquinelli, A. E.; Bálint, E.; Tuschl, T.; Zamore, P. D. (2001). "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA". Science. 293 (5531): 834–838. doi:10.1126/science.1062961. PMID 11452083.
• Hutvagner, G.; Zamore, P. D. (2002). "A microRNA in a Multiple-Turnover RNAi Enzyme Complex". Science. 297 (5589): 2056–2060. doi:10.1126/science.1073827. PMID 12154197.
• Schwarz, Dianne S.; Hutvágner, György; Du, Tingting; Xu, Zuoshang; Aronin, Neil; Zamore, Phillip D. (2003). "Asymmetry in the Assembly of the RNAi Enzyme Complex". Cell. 115 (2): 199–208. doi:10.1016/S0092-8674(03)00759-1. PMID 14567917.
• Tomari, Yukihide; Du, Tingting; Haley, Benjamin; Schwarz, Dianne S.; Bennett, Ryan; Cook, Heather A.; Koppetsch, Birgit S.; Theurkauf, William E.; Zamore, Phillip D. (2004). "RISC Assembly Defects in the Drosophila RNAi Mutant armitage". Cell. 116 (6): 831–841. doi:10.1016/S0092-8674(04)00218-1. PMID 15035985.
• Vagin, V. V.; Sigova, A.; Li, C.; Seitz, H.; Gvozdev, V.; Zamore, P. D. (2006). "A Distinct Small RNA Pathway Silences Selfish Genetic Elements in the Germline". Science. 313 (5785): 320–324. doi:10.1126/science.1129333. PMID 16809489.
• Tomari, Yukihide; Du, Tingting; Zamore, Phillip D. (2007). "Sorting of Drosophila Small Silencing RNAs". Cell. 130 (2): 299–308. doi:10.1016/j.cell.2007.05.057. PMC 2841505. PMID 17662944.
• Difiglia, M.; Sena-Esteves, M.; Chase, K.; Sapp, E.; Pfister, E.; Sass, M.; Yoder, J.; Reeves, P.; Pandey, R. K.; Rajeev, K. G.; Manoharan, M.; Sah, D. W. Y.; Zamore, P. D.; Aronin, N. (2007). "Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits". Proceedings of the National Academy of Sciences. 104 (43): 17204–17209. doi:10.1073/pnas.0708285104. PMC 2040405. PMID 17940007.
• Ghildiyal, M.; Seitz, H.; Horwich, M. D.; Li, C.; Du, T.; Lee, S.; Xu, J.; Kittler, E. L.W.; Zapp, M. L.; Weng, Z.; Zamore, P. D. (2008). "Endogenous siRNAs Derived from Transposons and mRNAs in Drosophila Somatic Cells". Science. 320 (5879): 1077–1081. doi:10.1126/science.1157396. PMC 2953241. PMID 18403677.
• Ameres, S. L.; Horwich, M. D.; Hung, J.-H.; Xu, J.; Ghildiyal, M.; Weng, Z.; Zamore, P. D. (2010). "Target RNA-Directed Trimming and Tailing of Small Silencing RNAs". Science. 328 (5985): 1534–1539. doi:10.1126/science.1187058. PMC 2902985. PMID 20558712.
• Salomon, William E.; Jolly, Samson M.; Moore, Melissa J.; Zamore, Phillip D.; Serebrov, Victor (2015). "Single-Molecule Imaging Reveals that Argonaute Reshapes the Binding Properties of its Nucleic Acid Guides". Cell. 162 (1): 84–95. doi:10.1016/j.cell.2015.06.029. PMC 4503223. PMID 26140592.